Moderna’s mRNA vaccine has 94.1% efficacy in final analysis, has applied for EUA

Moderna's mRNA vaccine has 94.1% efficacy in the final analysis of the Phase-3 trial involving 30,000 participants. The vaccine has 100% efficacy in preventing severe disease and is efficacious even in older adults aged over 65 years. As the Phase-3 trial has exceeded two months of median follow-up post vaccination as required by the U.S … Continue reading Moderna’s mRNA vaccine has 94.1% efficacy in final analysis, has applied for EUA

Ethics of denying COVID-19 vaccine to placebo group participants once EUA is granted

Offering the vaccine right away to those in the placebo group will first require unblinding the study. Unblinding the study and offering the vaccine to the placebo group will make it almost impossible to gather further information on vaccine efficacy, thus making full licensure challenging.

More mRNA COVID-19 vaccines show stability at higher temperatures

The interim results of Moderna’s mRNA vaccine show that the vaccine has 94.5% efficacy in preventing COVID-19. But the striking difference between Pfizer's and Moderna vaccine lies in thermostability at relatively higher temperatures. The Moderna vaccine is stable at -20 degree C for up to six months, 2-8 degree C for 30 days, and at … Continue reading More mRNA COVID-19 vaccines show stability at higher temperatures

Moderna’s coronavirus vaccine is safe, immunogenic, interim phase-1 results show

Moderna’s candidate mRNA vaccine for novel coronavirus has no safety issues and is able to elicit immune responses in all the 45 participants, the interim Phase-1 results show. Phase-2 trial is under way and Phase-3 is set to begin later this month. The interim Phase-1 analysis of Moderna’s candidate vaccine mRNA-1273 for novel coronavirus has … Continue reading Moderna’s coronavirus vaccine is safe, immunogenic, interim phase-1 results show

Moderna’s coronavirus vaccine is safe, interim results of phase-1 trial shows

Interim results of Moderna’s phase-1 human clinical trial of novel coronavirus vaccine (mRNA-1273) shows the vaccine is safe. The vaccine was also able to elicit neutralizing antibodies. Interim results of Moderna’s phase-1 human clinical trial of novel coronavirus vaccine (mRNA-1273) that uses messenger RNA (mRNa) shows the vaccine is safe. The vaccine was also able … Continue reading Moderna’s coronavirus vaccine is safe, interim results of phase-1 trial shows